Table 1.
NGS Results Detected Before and After Treatment with Trastuzumab and Lapatinib
| Genes | 20171018 Before Trastuzumab with Lapatinib |
20180820 After Resistance to Trastuzumab with Lapatinib |
Methodology | ||||
|---|---|---|---|---|---|---|---|
| Variations | Abundance | CN | Variations | Abundance | CN | ||
| HER2 | CNG | 2.1 | CNG | 7.7 | NGS | ||
| p.R157W | 2.0% | NGS | |||||
| TP53 | p.L257R | 6.4% | p.L257R | 49.9% | NGS | ||
| CDK12 | CNG | 1.8 | Negative | NGS | |||
| NSD1 | GF | 0.2% | Negative | NGS | |||
| ESR1 | Negative | Negative | NGS | ||||
| BRCA1 | Negative | Negative | NGS | ||||
| BRCA2 | Negative | Negative | NGS | ||||
Abbreviations: HER2, human epidermal growth factor receptor-2; TP53, tumor protein p53; CDK12, cyclin-dependent kinase 12; NSD1, nuclear receptor binding SET domain protein 1; ESR1, estrogen receptor 1; BRCA1, breast cancer susceptibility gene 1; BRCA2, breast cancer susceptibility gene 2; CNG, copy number gain; CN, copy number; GF, gene fusion; NGS, next-generation sequencing.